205 related articles for article (PubMed ID: 32135040)
1. Tamoxifen is a candidate first-in-class inhibitor of acid ceramidase that reduces amitotic division in polyploid giant cancer cells-Unrecognized players in tumorigenesis.
White-Gilbertson S; Lu P; Jones CM; Chiodini S; Hurley D; Das A; Delaney JR; Norris JS; Voelkel-Johnson C
Cancer Med; 2020 May; 9(9):3142-3152. PubMed ID: 32135040
[TBL] [Abstract][Full Text] [Related]
2. Polyploid giant cancer cells are dependent on cholesterol for progeny formation through amitotic division.
White-Gilbertson S; Lu P; Esobi I; Echesabal-Chen J; Mulholland PJ; Gooz M; Ogretmen B; Stamatikos A; Voelkel-Johnson C
Sci Rep; 2022 May; 12(1):8971. PubMed ID: 35624221
[TBL] [Abstract][Full Text] [Related]
3. Genetic and pharmacological inhibition of acid ceramidase prevents asymmetric cell division by neosis.
White-Gilbertson S; Lu P; Norris JS; Voelkel-Johnson C
J Lipid Res; 2019 Jul; 60(7):1225-1235. PubMed ID: 30988134
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.
Morad SA; Cabot MC
Biochim Biophys Acta; 2015 Sep; 1851(9):1134-45. PubMed ID: 25964209
[TBL] [Abstract][Full Text] [Related]
5. Ceramide Synthase 6 Maximizes p53 Function to Prevent Progeny Formation from Polyploid Giant Cancer Cells.
Lu P; White-Gilbertson S; Beeson G; Beeson C; Ogretmen B; Norris J; Voelkel-Johnson C
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34062962
[TBL] [Abstract][Full Text] [Related]
6. Genistein stimulates MCF-7 breast cancer cell growth by inducing acid ceramidase (ASAH1) gene expression.
Lucki NC; Sewer MB
J Biol Chem; 2011 Jun; 286(22):19399-409. PubMed ID: 21493710
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome analysis of polyploid giant cancer cells and their progeny reveals a functional role for p21 in polyploidization and depolyploidization.
White-Gilbertson S; Lu P; Saatci O; Sahin O; Delaney JR; Ogretmen B; Voelkel-Johnson C
J Biol Chem; 2024 Apr; 300(4):107136. PubMed ID: 38447798
[TBL] [Abstract][Full Text] [Related]
8. Targeting ceramide metabolic pathway induces apoptosis in human breast cancer cell lines.
Vethakanraj HS; Babu TA; Sudarsanan GB; Duraisamy PK; Ashok Kumar S
Biochem Biophys Res Commun; 2015 Aug; 464(3):833-9. PubMed ID: 26188095
[TBL] [Abstract][Full Text] [Related]
9. Novel off-target effect of tamoxifen--inhibition of acid ceramidase activity in cancer cells.
Morad SA; Levin JC; Tan SF; Fox TE; Feith DJ; Cabot MC
Biochim Biophys Acta; 2013 Dec; 1831(12):1657-64. PubMed ID: 23939396
[TBL] [Abstract][Full Text] [Related]
10. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
Osborne CK; Bardou V; Hopp TA; Chamness GC; Hilsenbeck SG; Fuqua SA; Wong J; Allred DC; Clark GM; Schiff R
J Natl Cancer Inst; 2003 Mar; 95(5):353-61. PubMed ID: 12618500
[TBL] [Abstract][Full Text] [Related]
11. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q
Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135
[TBL] [Abstract][Full Text] [Related]
12. Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer.
Sänger N; Ruckhäberle E; Györffy B; Engels K; Heinrich T; Fehm T; Graf A; Holtrich U; Becker S; Karn T
Mol Oncol; 2015 Jan; 9(1):58-67. PubMed ID: 25131496
[TBL] [Abstract][Full Text] [Related]
13. IGFBP-1 Expression Promotes Tamoxifen Resistance in Breast Cancer Cells via Erk Pathway Activation.
Zheng Y; Sowers JY; Houston KD
Front Endocrinol (Lausanne); 2020; 11():233. PubMed ID: 32435229
[TBL] [Abstract][Full Text] [Related]
14. A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1.
Ming J; Ruan S; Wang M; Ye D; Fan N; Meng Q; Tian B; Huang T
Oncotarget; 2015 Dec; 6(38):40692-703. PubMed ID: 26517687
[TBL] [Abstract][Full Text] [Related]
15. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
[TBL] [Abstract][Full Text] [Related]
17. Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
Jeong SB; Im JH; Yoon JH; Bui QT; Lim SC; Song JM; Shim Y; Yun J; Hong J; Kang KW
Mol Cancer Ther; 2018 Apr; 17(4):825-837. PubMed ID: 29437878
[TBL] [Abstract][Full Text] [Related]
18. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
19. Sphingolipids in embryonic development, cell cycle regulation, and stemness - Implications for polyploidy in tumors.
Voelkel-Johnson C
Semin Cancer Biol; 2022 Jun; 81():206-219. PubMed ID: 33429049
[TBL] [Abstract][Full Text] [Related]
20. AMPK Activation and Metabolic Reprogramming by Tamoxifen through Estrogen Receptor-Independent Mechanisms Suggests New Uses for This Therapeutic Modality in Cancer Treatment.
Daurio NA; Tuttle SW; Worth AJ; Song EY; Davis JM; Snyder NW; Blair IA; Koumenis C
Cancer Res; 2016 Jun; 76(11):3295-306. PubMed ID: 27020861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
